Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial

MLA

Alexander P. J. Vlaar, et al. “Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial.” SSRN Electronic Journal, Jan. 2020. EBSCOhost, https://doi.org/10.2139/ssrn.3658226.

APA

Alexander P. J. Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, Esther B. Bulle, Frank E.H.P. van Baarle, Marcel C.G. van de Poll, E. Marleen Kemper, Iwan C.C. van der Horst, Marcus J. Schultz, Janneke Horn, Frederique Paulus, Lieuwe D. Bos, W. Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, … Diederik van de Beek. (2020). Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3658226

Chicago

Alexander P. J. Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, et al. 2020. “Anti-C5a Antibody (IFX-1) Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial.” SSRN Electronic Journal, January. doi:10.2139/ssrn.3658226.